GPT and metabolic syndrome: Baseline ALT was associated with a lower risk of metabolic syndrome in Model 1 (HR 0.992, 95% CI 0.988–0.997, p = 0.001).Similar to AST, this was also attenuated in Model 4 after adjusting for covariates (p = 0.075).